Plain-English translation of NCT07067905 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new imaging agent called that helps doctors see certain types of cancer more clearly during PET scans. The study involves patients who have either glioblastoma (a serious brain tumor) or a specific type of kidney cancer. Researchers want to understand how safe this new medication is and how well it works at finding these cancers compared to standard imaging methods.
Current imaging methods can sometimes miss or unclear show these aggressive cancers, which makes it harder for doctors to plan the best treatment. This trial aims to see if the new treatment offers a better way to spot these cancers early and accurately.
You likely qualify if…
You likely don't qualify if…
You would receive an intravenous injection of the new imaging medication, followed by a PET scan to see how the medication behaves in your body. Within a four-week period, you would also have a standard imaging scan (either a different PET scan or an MRI-type scan, depending on your cancer type) so doctors can compare the two methods. The study team will monitor you for any side effects and collect information about how well the new medication works.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China